CEO of Ligand Innovation Global, Dr. Dayo Olakulehin confirmed on August 4, 2021 that Ligand achieved significant breakthroughs in development of latest prototype of the LifeAir G1 portable ventilator. Ligand Innovation Global, Inc., is a partially owned company and partner of Forwardly, Inc. (OTCMKTS:FORW).
The company’s engineering team has designed an airway circuitry delivering maximal tidal volumes despite maximum lung resistance. Dr. Olakulehin said that basically the device works as it has been tested on a calibrated test lung.
The system delivered consistent tidal volume despite changes to volume and tubing length.
The firm’s next steps will be on building 3D printed mock-up of the bag compression mechanism as well as producing extensive data on the circuitry.
The final build of the prototype is likely to be in October and FDA submission will be done by December 2021. Dr Olakulehin said that supply chain issues remain challenging but the firm is optimistic on submitting ahead of the current target date.
Forwardly’s Medical Board of Advisors member, Dr. Michael Soffer said that the results are encouraging and engineers can see the results. Soffer said that he is keen on flying to Mississauga and watching functioning of the prototype as the world urgently needs a device like this.
Forwardly is an opportunity investor seeking to partner in fresh ideas.
FORW stock is up by 13.64% to $0.12 in the morning session on Wednesday.
 Stock Attempts To Bounce Back: What’s The Buzz?){kind=link}